Journal of Neural Transmission

, 114:1027

Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation

  • J. Kehr
  • X.-J. Hu
  • M. Goiny
  • D. K. A. Scheller
Short communication

DOI: 10.1007/s00702-007-0719-3

Cite this article as:
Kehr, J., Hu, XJ., Goiny, M. et al. J Neural Transm (2007) 114: 1027. doi:10.1007/s00702-007-0719-3

Summary

Rotigotine, a non-ergolinic dopamine receptor agonist for treatment of Parkinson’s disease was continuously administered over 48 h (0.5 mg/kg s.c., slow release formulation) to conscious rats striatally implanted with a microdialysis probe. Subsequently, the levels of rotigotine increased to a maximum of 3.42 + 2.1 nmol/l and remained at a level of 2.81 ± 0.82 nmol/l for 48 h. Concomitantly, the dopamine levels consistently decreased to 20% of the control level. This suggests that the sustained administration of rotigotine provides stable extracellular drug levels in the striatum resulting in continuous stimulation of dopamine receptors.

Keywords: Parkinson’s disease, treatment, dyskinesia, rat, microdialysis, extracellular drug concentration, pharmacokinetics 

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • J. Kehr
    • 1
    • 2
  • X.-J. Hu
    • 2
  • M. Goiny
    • 1
  • D. K. A. Scheller
    • 3
  1. 1.Department of Physiology and PharmacologyKarolinska InstitutetStockholmSweden
  2. 2.Pronexus Analytical AB, Karolinska Science ParkStockholmSweden
  3. 3.Department of Pharmacology/ToxicologySchwarz BiosciencesMonheimGermany

Personalised recommendations